{"schema_version":"1","generated_at":"2026-11-11T22:31:51.731Z","data_as_of":"2026-11-09","url":"https://www.findmykol.com/kol/antonio-calles","json_url":"https://www.findmykol.com/kol/antonio-calles/profile.json","record_kind":"full","profile_kind":"research","person":{"slug":"antonio-calles","name":"Antonio Calles","title":"Head of the Lung Cancer Unit, Hospital Ruber Internacional (Quirónsalud), Madrid","specialty":"Medicine","therapeutic_area":"Lung","therapeutic_areas":["Lung","Oncology"],"institution":"Hospital Ruber Internacional (Quirónsalud)","institution_url":"https://www.findmykol.com/institution/hospital-ruber-internacional-quir-nsalud","country":{"name":"Spain","code":"ES","status":"provisional"},"register":{"country":"ES"}},"identifiers":{"orcid":"0000-0002-2547-1947","openalex":"A5090452503"},"summary":"Antonio Calles is Head of the Lung Cancer Unit, Hospital Ruber Internacional (Quirónsalud), Madrid at Hospital Ruber Internacional (Quirónsalud). OpenAlex indexes 211 publications with 4,535 citations (h-index 36); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.","overview":{"text":"Antonio Calles is Head of the Lung Cancer Unit, Hospital Ruber Internacional (Quirónsalud), Madrid. The public record shows 211 publications with 4,535 citations (h-index 36), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies. It also documents an investigator role on 5 registered clinical trials.","bullets":["Most recent indexed publication: 2026 · Clinical cancer research","Top research focus: Lung Cancer Treatments and Mutations","5 registered trials on ClinicalTrials.gov"],"generated_at":"2026-11-11"},"focus":{"indications":[{"label":"Lung Cancer (NSCLC/SCLC)","therapeutic_area":"Oncology","trials":4,"topics":0,"strength":13},{"label":"Small Cell Lung Carcinoma","therapeutic_area":"Oncology","trials":4,"topics":0,"strength":12},{"label":"Melanoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":4},{"label":"Lymphoma","therapeutic_area":"Oncology","trials":1,"topics":0,"strength":3},{"label":"Breast Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Colorectal Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"COVID-19","therapeutic_area":"Infectious Disease","trials":0,"topics":0,"strength":1},{"label":"Gastroesophageal Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Neuro-Oncology / Glioma","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Pancreatic Cancer","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Sarcoma","therapeutic_area":"Oncology","trials":0,"topics":0,"strength":1},{"label":"Thyroid Disorders","therapeutic_area":"Endocrinology/Metabolic","trials":0,"topics":0,"strength":1}],"research_topics":["Lung Cancer Treatments and Mutations","Lung Cancer Diagnosis and Treatment","Lung Cancer Research Studies","Cancer Genomics and Diagnostics","Cancer Immunotherapy and Biomarkers"],"drugs_studied":{"total":2,"shown":2,"withheld":0,"rows":[{"name":"Alectinib","trials":1,"payments":0,"publications":0,"mentions":1},{"name":"Neladalkib","trials":1,"payments":0,"publications":0,"mentions":1}]},"works_with":{"total":5,"shown":3,"withheld":2,"rows":[{"name":"Antonio Calles Blanco","trials":1,"payments":0,"mentions":1},{"name":"Eli Lilly and Company","trials":1,"payments":0,"mentions":1},{"name":"Fundación GECP","trials":1,"payments":0,"mentions":1}]}},"scholarship":{"works_count":211,"cited_by_count":4535,"h_index":36,"i10_index":70,"pubmed_count":16,"latest_activity_year":2026,"source":"works"},"trials":{"count":5,"shown":3,"withheld":2,"matched_by":"identity-adjudicated record","rows":[{"nct":"NCT06890598","title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","phase":"PHASE3","status":"RECRUITING","role":"Investigator","sponsor":"Eli Lilly and Company","source_url":"https://clinicaltrials.gov/study/NCT06890598","trial_url":"https://www.findmykol.com/trial/NCT06890598"},{"nct":"NCT06765109","title":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","phase":"PHASE3","status":"RECRUITING","role":"Investigator","sponsor":"Nuvalent Inc.","source_url":"https://clinicaltrials.gov/study/NCT06765109","trial_url":"https://www.findmykol.com/trial/NCT06765109"},{"nct":"NCT05167500","title":"Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment","status":"COMPLETED","role":"Investigator","sponsor":"Fundación GECP","source_url":"https://clinicaltrials.gov/study/NCT05167500","trial_url":"https://www.findmykol.com/trial/NCT05167500"}],"source":"trials"},"payments":{"note":"Not attributed. This person has no U.S. clinical registration (NPI) on file, so industry payments cannot be reliably tied to them."},"funding":{"award_count":0,"rows_total":0,"shown":0,"withheld":0,"rows":[],"source":"grants"},"congress":{"count":58,"years":{"first":2011,"last":2026},"societies":["AACR","AHA","ASCO","ESMO","IASLC","ISPOR Europe"],"shown":3,"withheld":55,"rows":[{"title":"Abstract 2434: Prognostic and predictive effects of TP53 co-mutations and RET fusion partners in RET -rearranged advanced NSCLC","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-2434","source_url":"https://doi.org/10.1158/1538-7445.am2026-2434","status":"verified"},{"title":"Abstract CT248: Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib","society":"AACR","meeting":"AACR Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1158/1538-7445.am2026-ct248","source_url":"https://doi.org/10.1158/1538-7445.am2026-ct248","status":"verified"},{"title":"Efficacy and safety of pralsetinib as first-line treatment of RET fusion–positive advanced or metastatic non–small cell lung cancer (NSCLC): The phase 3 AcceleRET-Lung study.","society":"ASCO","meeting":"ASCO Annual Meeting","year":2026,"role":"co_author","presentation_type":"unknown","contribution_type":"abstract","doi":"https://doi.org/10.1200/jco.2026.44.16_suppl.8504","source_url":"https://doi.org/10.1200/jco.2026.44.16_suppl.8504","status":"verified"}],"source":"congress"},"publications":{"total":16,"shown":5,"withheld":11,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.","year":2026,"journal":"Clinical cancer research : an official journal of the American Association for Cancer Research","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42873584/","status":"verified"},{"title":"Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.","year":2026,"journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42607282/","status":"verified"},{"title":"Real-World Data of First-Line Cemiplimab Monotherapy for Metastatic Non-Small Cell Lung Cancer (NSCLC) with PD-L1 Expression ≥ 50%: A National Spanish Multicentric Cohort (CEMI-SPA Study).","year":2025,"journal":"Cancers","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41301009/","status":"verified"},{"title":"Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials.","year":2025,"journal":"Cancer communications (London, England)","types":["Journal Article","Clinical Trial, Phase I","Clinical Trial, Phase II"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41037823/","status":"verified"},{"title":"Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.","year":2025,"journal":"Molecular cancer therapeutics","types":["Journal Article","Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/39636909/","status":"verified"}],"source":"publications"},"presence":{"owned_accounts":{"total":1,"shown":1,"rows":[{"platform":"linkedin","url":"https://www.linkedin.com/in/antonio-calles-776b8145","status":"verified"}]},"verified_means":"confirmed in more than one place; provisional means found and still being confirmed"},"recognition":{"education":{"total":2,"shown":2,"rows":[{"value":"Medical degree, Universidad Autónoma de Madrid","source_url":"https://www.comunidad.madrid/hospital/gregoriomaranon/sites/gregoriomaranon/files/2019-11/cv_antonio_calles.pdf","status":"provisional","collected_at":"2026-11-09"},{"value":"Specialist in Medical Oncology (Médico Especialista en Oncología Médica)","source_url":"https://www.comunidad.madrid/hospital/gregoriomaranon/sites/gregoriomaranon/files/2019-11/cv_antonio_calles.pdf","status":"provisional","collected_at":"2026-11-09"}]},"roles":{"total":2,"shown":2,"rows":[{"value":"Associate Editor, Frontiers (journal section not confirmed; listed as Associate Editor for Thoracic Oncology on Frontiers Oncology editors page)","source_url":"https://theorg.com/org/frontiers/org-chart/antonio-calles","status":"provisional","collected_at":"2026-11-09"},{"value":"Faculty member, Lung and other Thoracic Tumours group, European Society for Medical Oncology (ESMO)","source_url":"https://www.quironsalud.com/ruber-internacional/en/medical-staff/antonio-calles-blanco","status":"provisional","collected_at":"2026-11-09"}]},"secondary_affiliations":{"total":2,"shown":2,"rows":[{"value":"Hospital General Universitario Gregorio Marañón, Madrid (listed as affiliation; 2019 CV describes thoracic tumor unit post)","source_url":"https://dev.lungsummit.org/?p=27012127","status":"provisional","collected_at":"2026-11-09"},{"value":"Hospital General Universitario Gregorio Marañón: Médico Especialista en Oncología Médica, Unidad de tumores torácicos (CV dated 2019)","source_url":"https://www.comunidad.madrid/hospital/gregoriomaranon/sites/gregoriomaranon/files/2019-11/cv_antonio_calles.pdf","status":"provisional","collected_at":"2026-11-09"}]},"media":{"total":2,"shown":2,"rows":[{"value":"Quirónsalud interview: \"Dr. Antonio Calles: Debemos huir del estigma que produce el tabaquismo en las personas que padecen cáncer de pulmón\"","source_url":"https://www.quironsalud.com/es/comunicacion/actualidad/dr-antonio-calles-debemos-huir-estigma-produce-tabaquismo-p","status":"provisional","collected_at":"2026-11-09"},{"value":"Oncodaily expert commentary: \"Antonio Calles: 4th Generation ROS1 TKI Shows Outstanding Efficacy in 1L NSCLC\"","source_url":"https://oncodaily.com/voices/antonio-calles-nsclc-586238","status":"provisional","collected_at":"2026-11-09"}]}},"similar":[{"name":"Ignacio Wistuba","slug":"ignacio-wistuba","institution":"Moffitt Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/ignacio-wistuba","json_url":"https://www.findmykol.com/kol/ignacio-wistuba/profile.json"},{"name":"Pasi Janne","slug":"pasi-janne","institution":"Dana-Farber Cancer Institute","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/pasi-janne","json_url":"https://www.findmykol.com/kol/pasi-janne/profile.json"},{"name":"Julie Brahmer","slug":"julie-brahmer","institution":"Johns Hopkins University School of Medicine","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/julie-brahmer","json_url":"https://www.findmykol.com/kol/julie-brahmer/profile.json"},{"name":"Enriqueta Felip","slug":"enriqueta-felip","institution":"Vall d'Hebron Institute of Oncology (VHIO)","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/enriqueta-felip","json_url":"https://www.findmykol.com/kol/enriqueta-felip/profile.json"}],"coverage":{"note":"An identity-adjudicated profile: every section above was checked. Where a section states a count of zero, the public record was searched and nothing was found."},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":2,"congress":55,"publications":11}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-11-09"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies","collected_at":"2026-11-09"},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"},"congress":{"name":"OpenAlex","url":"https://openalex.org","provides":"DOI-verified congress abstracts across AACR, ASCO, ASH, ASTRO, ESMO","disclaimer":"Congress abstracts are published as DOI-bearing journal supplements and attributed via the same ORCID-disambiguated authorship as publications.","collected_at":"2026-11-09"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-11-09"}},"methodology_url":"https://www.findmykol.com/about#methodology"}